Drug Allergy in Special Populations: From Pathogenesis to Practical Applications

This course is part of the 2017 Virtual Annual Meeting.  Want more virtual meeting recordings?  Save by ordering the full set!

Session 1801 from the 2017 AAAAI Annual Meeting seeks to answer questions related to the prevalence, impact and underlying pathogenesis of drug allergy to commonly employed therapeutics in special and vulnerable populations and provides examples of drug allergy clinics in diverse settings. This session will also seek to provide a framework for understanding the causal mechanisms and approaches to different populations with key challenges in different drug allergy syndromes.

Key questions asked and answered would be:

  1. What is the approach to the management of a patient who develops a drug allergy syndrome on multiple necessary drugs (such as with anti-tuberculous or antiretroviral agents)?
  2. What are the key mechanisms of delayed hypersensitivity and what has antiretroviral therapy taught us about this?
  3. What strategies are available to manage patients with delayed drug reactions including desensitization, treating through and diagnostic testing?
  4. What is new in the management of allergic reactions to biological agents and chemotherapy?
  5. What is known about the mechanisms of reactions associated chemotherapeutic agents and biologicals including immediate (IgE and non-IgE), injection site reactions and delayed reactions?

AMA PRA Category 1 Credits™: 1.25
CE: 1.25

Credit must be claimed by May 31, 2019.  Any credit request on or after June 1, 2019 will be subject to an administrative fee.

Target Audience

Physicians
Allergists/Immunologists
Nurses
Nurse Practitioners
Allied Health Professionals

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss key challenges and strategies involved in the management of drug allergy in special treatment populations and the value of a multidisciplinary clinic model
  • Describe approaches to the prevention, diagnosis and management of delayed hypersensitivity reactions and lessons learned from antiretroviral drugs as a mechanistic model
  • Discuss reactions among immuncompromised hosts
Summary
Available credit: 
  • 1.25 Attendance
    Attendance credit.
  • 1.25 CE
    CE credit.
  • 1.25 CME
    CME credit.
Course opens: 
05/31/2017
Course expires: 
05/31/2019
Cost:
$25.00
Rating: 
0

Reviewers
Thomas Miller, MD FAAAAI

Allergy Associates of Western Michigan, Grandville, MI
Relevant relationships: Patent holder for new pulmonary function device

Karen Gregory, DNP APRN-BC RRT AE-C
Oklahoma Allergy and Asthma Clinic, Edmond, OK
Relevant relationships: Merck, MEDA and Novartis: speakers bureau

Anne Ditto, MD FAAAAI
Northwestern University Feinberg School of Medicine, Chicago, IL
Relevant relationships: None

Robert Corriel, MD FAAAAI
Manhasset Allergy and Asthma Associates, Manhasset, NY
Relevant relationships: None

Faculty
Jonathan A. Bernstein, MD FAAAAI
Bernstein Allergy Group, Inc., Cincinnati, OH
Relevant relationships: None

David Khan, MD FAAAAI
University of Texas Southwestern, Dallas, TX
Relevant relationships: None

Jonathan G. Peter, MD PhD
University of Cape Town/Western Cape Provincial Health, Cape Town, South Africa
Relevant relationships: None

Elizabeth J. Phillips, MD FAAAAI
Vanderbilt University, Evensville, TN
Relevant relationships: None

Mariana C. Castells, MD PhD FAAAAI
Brigham and Women's Hospital, Boston, MA
Relevant relationships: None

AAAAI Disclosure Policy
Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, authors and reviewers are required to disclose all relationships that meet the following parameters:

  • Employment. Name of employer and job title.
  • Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
  • Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
  • Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
  • Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
  • Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
  • Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.

Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Designation Statement
The American Academy of Allergy, Asthma, & Immunology (AAAAI) is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 1.25 Contact Hours.

Medium and Method of Physician Participation for an Enduring Activity
Follow these steps to complete the activity:

  1. Register for the activity.
  2. Review the CME Info Page.
  3. Complete all required components.
  4. Complete the post-test. You must achieve a score of 70% or higher on post-tests to claim credit.
  5. Complete the activity evaluation.
  6. Claim your credits. Enter only the number of credits earned based on your participation in the activity.
  7. Print or save your certificate.

AAAAI Privacy Policy
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.

Release date
Original release date: June 1, 2017.  Valid for credit through May 31, 2019.

Questions
Activity-related questions should be directed to cme@aaaai.org

Available Credit

  • 1.25 Attendance
    Attendance credit.
  • 1.25 CE
    CE credit.
  • 1.25 CME
    CME credit.

Accreditation Period

Course opens: 
05/31/2017
Course expires: 
05/31/2019

Price

Cost:
$25.00
Please login or register to take this course.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari.

Internet Explorer is no longer supported.